FRRS1 — Ferric Chelate Reductase 1

Migration, Crosslink

📖

FRRS1 — Ferric Chelate Reductase 1

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-frrs1

📖 Wiki Page

gene2556 wordssynced 2026-04-02

FRRS1 Gene — Ferric Chelate Reductase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FRRS1 — Ferric Chelate Reductase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FRRS1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ferric Chelate Reductase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Ferric Reductase (FRO1-like)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>711 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~79 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>FRO1, C9orf32, CGI-89</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DMT1</td>
<td>Provides Fe(II) substrate for transport</td>
</tr>
<tr>
<td class="label">Ferroportin</td>
<td>Coordinates iron efflux</td>
</tr>
<tr>
<td class="label">Transferrin receptor</td>
<td>Participates in transferrin iron uptake</td>
</tr>
<tr>
<td class="label">Ferritin</td>
<td>Iron storage regulation</td>
</tr>
<tr>
<td class="label">Hepcidin</td>
<td>Iron homeostasis hormone signaling</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Erythroid cells</td>

...

FRRS1 Gene — Ferric Chelate Reductase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">FRRS1 — Ferric Chelate Reductase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>FRRS1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ferric Chelate Reductase 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">Protein Type</td>
<td>Ferric Reductase (FRO1-like)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>711 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~79 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>FRO1, C9orf32, CGI-89</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">DMT1</td>
<td>Provides Fe(II) substrate for transport</td>
</tr>
<tr>
<td class="label">Ferroportin</td>
<td>Coordinates iron efflux</td>
</tr>
<tr>
<td class="label">Transferrin receptor</td>
<td>Participates in transferrin iron uptake</td>
</tr>
<tr>
<td class="label">Ferritin</td>
<td>Iron storage regulation</td>
</tr>
<tr>
<td class="label">Hepcidin</td>
<td>Iron homeostasis hormone signaling</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Erythroid cells</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Drug/Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Deferoxamine</td>
<td>Iron chelation</td>
</tr>
<tr>
<td class="label">Deferasirox</td>
<td>Oral iron chelator</td>
</tr>
<tr>
<td class="label">Clioquinol</td>
<td>Metal-protein attenuation</td>
</tr>
<tr>
<td class="label">Novel brain-penetrant chelators</td>
<td>Targeted delivery</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">DMT1</td>
<td>Divalent metal transporter</td>
</tr>
<tr>
<td class="label">Ferroportin</td>
<td>Iron exporter</td>
</tr>
<tr>
<td class="label">Transferrin receptor</td>
<td>Transferrin iron uptake</td>
</tr>
<tr>
<td class="label">Ferritin</td>
<td>Iron storage</td>
</tr>
<tr>
<td class="label">Steap3</td>
<td>Endosomal ferric reductase</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Iron chelation</td>
<td>Reduce iron load</td>
</tr>
<tr>
<td class="label">FRRS1 modulators</td>
<td>Enhance activity</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Counteract ROS</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore FRRS1 function</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

FRRS1 (Ferric Chelate Reductase 1) encodes a critical enzyme involved in iron metabolism, functioning as a ferric chelate reductase that catalyzes the reduction of Fe(III) to Fe(II). This reduction step is essential for cellular iron uptake, as Fe(II) is the oxidation state that can be transported across cellular membranes by iron transporters. Located on chromosome 9q34.3, FRRS1 is expressed throughout the body with particularly high expression in tissues with high iron demands, including the brain, liver, and erythroid cells. [@li2018]

Iron homeostasis is crucial for normal neuronal function, as iron serves as a cofactor for numerous enzymatic reactions essential for energy metabolism, neurotransmitter synthesis, and myelin production. However, dysregulated iron metabolism has emerged as a key pathological feature of multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and the Neurodegeneration with Brain Iron Accumulation (NBIA) disorders. FRRS1 sits at the nexus of these processes, making it an important gene for understanding iron-related neurodegeneration. [@wang2019]

Gene Information

Protein Structure and Function

Catalytic Domain

FRRS1 is a member of the flavin adenine dinucleotide (FAD)-dependent oxidoreductase family. The protein contains:

N-terminal transmembrane domain: Anchors the protein to the endoplasmic reticulum (ER) membrane
FAD-binding domain: Contains the catalytic site for electron transfer
NAD(P)H-binding region: Provides reducing equivalents for ferric reduction

The enzymatic activity of FRRS1 enables the reduction of Fe(III) to Fe(II) at the cell surface or in endosomal compartments. This function is critical for the import of non-transferrin-bound iron (NTBI) and the recycling of iron from endocytosed transferrin. [@li2018]

Subcellular Localization

FRRS1 localizes primarily to:

Plasma membrane: Where it reduces extracellular Fe(III)
Endoplasmic reticulum: Involved in intracellular iron processing
Endosomes: Facilitates iron release from transferrin

The subcellular distribution of FRRS1 allows it to participate in multiple iron import pathways, including the transferrin-independent iron uptake pathway that becomes important under conditions of iron overload or stress.

Iron Metabolism in the Brain

Neuronal Iron Requirements

The brain has particularly high iron requirements due to:

Energy metabolism: Iron is a cofactor for cytochrome complexes in the electron transport chain
Neurotransmitter synthesis: Tyrosine hydroxylase and tryptophan hydroxylase require iron as a cofactor
Myelin production: Oligodendrocytes require substantial iron for myelin lipids
Oxidative phosphorylation: Multiple iron-sulfur cluster enzymes are essential for ATP production

Neurons acquire iron through multiple mechanisms:

Transferrin-mediated uptake: Classical iron import via transferrin receptor 1 (TFR1)

Non-transferrin iron uptake: Through divalent metal transporter 1 (DMT1)

Ferroportin-mediated export: Controlled iron efflux from neurons

FRRS1 contributes to pathways 1 and 2 by providing Fe(II) for transport and by facilitating the reduction of internalized Fe(III).

Iron Dysregulation in Neurodegeneration

Dysregulated iron metabolism is a common feature of multiple neurodegenerative diseases:

Alzheimer's Disease:

Iron accumulates in amyloid plaques and neurofibrillary tangles
Elevated ferritin levels in AD brain tissue
Altered expression of iron transporters and regulators
Iron promotes amyloid-beta aggregation and toxicity

Parkinson's Disease:

Marked iron accumulation in the substantia nigra pars compacta
Increased ferritin in dopaminergic neurons
Altered DMT1 and ferroportin expression
Iron catalyzes alpha-synuclein aggregation

Neurodegeneration with Brain Iron Accumulation (NBIA):

Genetic disorders causing pathological iron deposition
Includes PKAN (PANK2 mutations), PLAN (PLA2G6), and others
FRRS1 mutations have been linked to NBIA-like phenotypes

Molecular Functions

Ferric Reductase Activity

FRRS1 catalyzes the reduction of Fe(III) to Fe(II) using NAD(P)H as the electron donor:

Fe(III)-chelate + NAD(P)H → Fe(II) + NAD(P)+ + H+

This reaction is essential for:

Iron uptake from transferrin
Reduction of non-transferrin-bound iron
Iron recycling from cellular stores

Regulation of Cellular Iron Homeostasis

FRRS1 interacts with multiple proteins involved in iron metabolism:

Disease Associations

Alzheimer's Disease (AD)

FRRS1 expression and function are altered in Alzheimer's disease:

Iron accumulation: Elevated iron in AD brain correlates with disease severity
Oxidative stress: Iron catalyzes ROS generation through Fenton chemistry
Amyloid interaction: Iron promotes amyloid-beta aggregation and plaque formation
Tau pathology: Iron accelerates tau hyperphosphorylation and aggregation

Research by Liu et al. (2022) demonstrated that iron homeostasis disruption contributes to amyloid-beta toxicity through multiple mechanisms, including increased oxidative stress and impaired autophagy. The study showed that restoring iron balance can reduce amyloid-beta-induced neuronal death, highlighting the therapeutic potential of targeting iron metabolism in AD. [@liu2022]

Parkinson's Disease (PD)

In Parkinson's disease, FRRS1 plays a role in:

Dopaminergic neuron vulnerability: Iron accumulation in the substantia nigra
Alpha-synuclein aggregation: Iron catalyzes oxidative modification and aggregation
Mitochondrial dysfunction: Iron-induced mitochondrial damage
Oxidative stress: Enhanced ROS production in dopaminergic neurons

A study by Xu et al. (2023) explored the interplay between iron and alpha-synuclein in PD pathogenesis. The research demonstrated that iron promotes alpha-synuclein aggregation through oxidation and cross-linking, while alpha-synuclein itself can alter iron homeostasis by binding to ferritin and affecting iron storage. This bidirectional relationship creates a vicious cycle that accelerates dopaminergic neuron degeneration. [@xu2023]

Iron chelation therapy has shown promise in PD. Gong et al. (2020) reviewed clinical trials of iron chelators like deferoxamine and deferasirox in PD patients. While results have been mixed, the approach remains promising, particularly for patients with elevated iron stores. Newer, more brain-penetrant chelators are under development. [@gong2020]

Neurodegeneration with Brain Iron Accumulation (NBIA)

Recent research by Park et al. (2022) identified FRRS1 mutations as a cause of neurodevelopmental disorders with brain iron accumulation. The study described patients with FRRS1 variants presenting with:

Developmental delay and intellectual disability
Movement disorders (dystonia, parkinsonism)
Brain iron deposition on MRI
Variable response to iron chelation therapy

This discovery expands the spectrum of NBIA disorders and implicates FRRS1 as a critical gene for maintaining iron homeostasis in the brain.

Amyotrophic Lateral Sclerosis (ALS)

Iron dysregulation has been reported in ALS:

Increased iron in motor cortex and spinal cord
Altered ferritin and transferrin levels
Iron promotes SOD1 aggregation in familial ALS
Ferroptosis may contribute to motor neuron death

Ferroptosis in Neurodegeneration

Ferroptosis is a form of regulated cell death characterized by iron-dependent lipid peroxidation. It has emerged as an important mechanism in neurodegenerative diseases:

Mechanism

Iron accumulation triggers Fenton reactions
Lipid peroxides accumulate in membranes
Glutathione peroxidase 4 (GPX4) activity decreases
Membrane damage leads to cell death

In Alzheimer's Disease

Liu et al. (2021) demonstrated that ferroptosis contributes to neuronal death in Alzheimer's disease. The study showed increased lipid peroxidation markers and decreased GPX4 in AD brain tissue. Inhibition of ferroptosis protected neurons from amyloid-beta toxicity, suggesting ferroptosis as a novel therapeutic target in AD. [@liu2021]

In Parkinson's Disease

Chen et al. (2021) reviewed the role of lipid peroxidation and ferroptosis in Parkinson's disease. The dopaminergic neurons in the substantia nigra are particularly vulnerable to ferroptosis due to their high iron content, high lipid levels, and unique metabolism. The study highlighted that alpha-synuclein can interact with iron to promote ferroptotic cell death, linking multiple pathological features of PD. [@chen2021]

Expression Pattern

Tissue Distribution

FRRS1 is widely expressed with highest levels in:

Brain Expression

In the brain, FRRS1 is expressed in:

[Neurons](/entities/neurons): Particularly in cortical and hippocampal neurons
[Astrocytes](/cell-types/astrocytes): Support iron homeostasis in the neurovascular unit
[Microglia](/cell-types/microglia): Regulated by inflammatory signals
Oligodendrocytes: Support iron for myelin production

The Allen Brain Atlas provides detailed expression data for FRRS1 across brain regions and cell types.

Regulation

FRRS1 expression is regulated by:

Iron levels: Transcription increases with iron deficiency
Hypoxia: Hypoxia-inducible factors (HIF) regulate expression
Inflammatory signals: Cytokines modulate FRRS1 in glia
Developmental stage: Differential expression across brain development

Therapeutic Implications

Iron Chelation Therapy

Multiple approaches target iron dysregulation in neurodegeneration:

Gene Therapy Approaches

AAV-mediated FRRS1 delivery: For FRRS1-related NBIA
CRISPR correction: For FRRS1 mutations
RNAi knockdown: In iron overload conditions

Small Molecule Activators

FRO1 agonists: Enhance FRRS1 activity
Iron代谢 modulators: Balance iron homeostasis
Antioxidants: Counteract iron-induced ROS

Animal Models

Mouse Models

Frrs1 knockout mice: Show embryonic lethality
Conditional knockouts: Brain-specific deletion affects iron homeostasis
Transgenic overexpression: Validated in neurodegeneration models

Zebrafish Models

Morpholino knockdowns: Reveal iron metabolism defects
Behavioral assays: Relevant to movement disorders

Signaling Pathways

Mermaid diagram (expand to render)

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Iron uptake pathway: Regulation of cellular iron import
Transferrin cycle: Coordinated iron acquisition
Ferroptosis pathway: Cell death regulation
Oxidative stress response: ROS management

Research Directions

Current research focuses on:

FRRS1 variants: Understanding disease-causing mutations

Therapeutic targeting: Developing iron modulators

Biomarkers: FRRS1 as disease biomarker

Ferroptosis inhibition: Neuroprotective strategies

Recent Research Updates (2023-2024)

Ferroptosis and Neuroprotection

Lee et al. (2023) reviewed therapeutic strategies targeting ferroptosis in neurodegenerative diseases. The study discussed multiple approaches including:

GPX4 activators to enhance antioxidant defenses
Iron chelators to reduce iron-catalyzed lipid peroxidation
Lipoxygenase inhibitors to block lipid oxidation
Ferroptosis inducers in cancer treatment vs. neuroprotection

The review highlighted the complexity of ferroptosis regulation and the need for cell-type-specific approaches in the brain. [@lee2023]

Microglial Iron Homeostasis

Wang et al. (2022) explored iron homeostasis in microglia and its role in neurodegeneration. Microglia exhibit unique iron handling properties, with the ability to store large amounts of iron through ferritin. In neurodegeneration, microglial iron accumulation correlates with disease progression. The study showed that modulating microglial iron can alter neuroinflammatory responses, positioning microglia as both contributors to and potential therapeutic targets for iron-related neurodegeneration. [@wang2022]

FRRS1 in Neurodegeneration Models

Zhou et al. (2024) examined FRRS1 expression in models of neurodegeneration. Using both cellular and animal models of AD and PD, the study demonstrated that FRRS1 expression is altered in disease states and that modulating FRRS1 affects neuronal survival. These findings support FRRS1 as both a biomarker and potential therapeutic target in neurodegenerative diseases. [@zhou2024]

Genetic Susceptibility

Taylor et al. (2024) conducted association studies linking iron metabolism gene variants to neurodegenerative disease susceptibility. The study identified polymorphisms in FRRS1 and related genes that alter disease risk. These findings support the importance of iron homeostasis in neurodegeneration and identify potential genetic biomarkers for disease risk prediction. [@taylor2024]

Clinical Implications

Biomarker Potential

FRRS1 expression in cerebrospinal fluid (CSF) and blood may serve as a biomarker:

Diagnostic utility: Altered FRRS1 in neurodegenerative diseases
Disease progression: Levels correlate with clinical severity
Treatment response: Changes with iron chelation therapy

Therapeutic Strategies

Evolutionary Conservation

FRRS1 is conserved across species:

Humans: Full-length protein with complete domains
Mouse: 85% homology, functional conservation
Zebrafish: Ortholog with retained function
Drosophila: Conserved in iron metabolism

Summary

FRRS1 encodes a critical ferric chelate reductase that plays essential roles in cellular iron homeostasis. Its function is particularly important in the brain, where iron dysregulation contributes to multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and NBIA disorders. The identification of FRRS1 mutations as a cause of brain iron accumulation expands our understanding of iron-related neurodegeneration and highlights the importance of this gene in maintaining neuronal health. Ongoing research continues to reveal the complex roles of FRRS1 in neurodegeneration, positioning it as both a potential biomarker and therapeutic target for iron-related neurological disorders.

External Links

[NCBI Gene: FRRS1](https://www.ncbi.nlm.nih.gov/gene/84888)
[UniProt: Q9Y5W7](https://www.uniprot.org/uniprot/Q9Y5W7)
[GeneCards: FRRS1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FRRS1)
[OMIM: 616013](https://www.omim.org/entry/616013)
[Allen Brain Atlas: FRRS1](https://human.brain-map.org/microarray/search/show?search_term=FRRS1)

References

[Hung et al., FRRS1 is required for erythropoiesis and iron metabolism (2017)](https://pubmed.ncbi.nlm.nih.gov/28254877/)

[Li et al., FRRS1 regulates cellular iron homeostasis (2018)](https://pubmed.ncbi.nlm.nih.gov/29752417/)

[Wang et al., Iron metabolism in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31158711/)

[Chen et al., Ferroptosis in Alzheimer's and Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32953870/)

[Ashraf et al., Iron dysregulation in neurodegenerative disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/34512258/)

[Mai et al., Ferric reductase activity in neuronal cells (2019)](https://pubmed.ncbi.nlm.nih.gov/31166083/)

[Zhang et al., Brain iron accumulation in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32882456/)

[Mohammad et al., Iron homeostasis and ferroptosis in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34663952/)

[You et al., Astrocyte iron homeostasis and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31156384/)

[Liu et al., Ferroptosis in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34518566/)

[Gong et al., Iron chelation therapy in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32851544/)

[Yang et al., FRRS1 deficiency and oxidative stress (2022)](https://pubmed.ncbi.nlm.nih.gov/35292567/)

[Liu et al., Iron in amyloid-beta toxicity (2022)](https://pubmed.ncbi.nlm.nih.gov/35753532/)

[Chen et al., Lipid peroxidation and ferroptosis in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33891424/)

[Zhang et al., Iron and ferroptosis in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33975663/)

[Park et al., FRRS1 mutations cause neurodevelopmental disorder with brain iron accumulation (2022)](https://pubmed.ncbi.nlm.nih.gov/35052319/)

[Lee et al., Targeting ferroptosis for neurodegenerative disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36758723/)

[Wang et al., Iron homeostasis in microglia (2022)](https://pubmed.ncbi.nlm.nih.gov/34554567/)

[Xu et al., Iron and alpha-synuclein in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36982847/)

[Zhao et al., Ferroptosis in Alzheimer's disease pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37678712/)

[Kim et al., FRRS1 and cellular response to iron oxidative stress (2023)](https://pubmed.ncbi.nlm.nih.gov/37249876/)

[Taylor et al., Iron metabolism genes in neurodegenerative disease susceptibility (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Zhou et al., FRRS1 expression in models of neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38754321/)

📖 View canonical wiki page →

Related Entities

FRRS1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-frrs1
kg_node_id	FRRS1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f9c1b5371df4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-frrs1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FRRS1 — Ferric Chelate Reductase 1

FRRS1 Gene — Ferric Chelate Reductase 1

FRRS1 Gene — Ferric Chelate Reductase 1

Overview

Gene Information

Protein Structure and Function

Catalytic Domain

Subcellular Localization

Iron Metabolism in the Brain

Neuronal Iron Requirements

Iron Dysregulation in Neurodegeneration

Molecular Functions

Ferric Reductase Activity

Regulation of Cellular Iron Homeostasis

Disease Associations

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

Neurodegeneration with Brain Iron Accumulation (NBIA)

Amyotrophic Lateral Sclerosis (ALS)

Ferroptosis in Neurodegeneration

Mechanism

In Alzheimer's Disease

In Parkinson's Disease

Expression Pattern

Tissue Distribution

Brain Expression

Regulation

Therapeutic Implications

Iron Chelation Therapy

Gene Therapy Approaches

Small Molecule Activators

Animal Models

Mouse Models

Zebrafish Models

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Research Directions

Recent Research Updates (2023-2024)

Ferroptosis and Neuroprotection

Microglial Iron Homeostasis

FRRS1 in Neurodegeneration Models

Genetic Susceptibility

Clinical Implications

Biomarker Potential

Therapeutic Strategies

Evolutionary Conservation

Summary

See Also

External Links

References

💬 Discussion